Major advances have been made in cancer immunotherapy. One example is checkpoint blockade immunotherapy which has been approved by FDA to treat numerous cancer types resulting in a substantial increase in the number of lives saved. However, two major hurdles; low response rates, especially to poorly immunogenic cancers and immune-related adverse events (irAEs), limit its broader applications. Differently, a number of tumor ablation modalities have been studied to improve antitumor immunity, nevertheless, low potency is...